Alnylam Pharmaceuticals Inc (ALNY) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.

Total Assets Chart for Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc (ALNY) total assets for FY2025 were USD 5.0B, a 17.1% change from FY2024. Alnylam Pharmaceuticals Inc's total assets grew from USD 16.1M in 2002 to USD 5.0B in 2025 (30725.7% over 23 years). Total assets compound annual growth rate: 5-year CAGR of 7.8%, 10-year CAGR of 13.6%, 20-year CAGR of 21.7%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$31.65B
Implied Share Price
$236.56
Enterprise Value
$29.94B
Revenue (TTM)
$4.80B
EBITDA
$1.05B
Profit Margin
16.13%
Trailing P/E
41.65
Forward P/E
27.55
Price/Book (MRQ)
23.62
Price/Sales (TTM)
6.59
EV/EBITDA
27.09
EV/Revenue
6.23
Dividend Yield
—
Book Value
$10.12
Free Cash Flow (FY2025)
$465.38M
Free Cash Flow Yield
1.47%

Snapshot as of 28th August 2026 — not point-in-time controlled, may lag the live market by a few days.